Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study
| Autor: | A Gorins, J Blonk-Van Der Wijst, H Maass, J Michel, H Nowakowski, E Engelsman, Jean-Claude Heuson, A Drochmans |
|---|---|
| Rok vydání: | 1975 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Pyrrolidines Nafoxidine Advanced breast Remission Spontaneous Administration Oral Breast Neoplasms Spontaneous remission Ethinyl Estradiol law.invention Breast cancer Randomized controlled trial law Internal medicine Humans Medicine Aged General Environmental Science Gynecology Clinical Trials as Topic business.industry General Engineering Cancer General Medicine Middle Aged Comparative trial medicine.disease Menopause General Earth and Planetary Sciences Female business hormones hormone substitutes and hormone antagonists Research Article medicine.drug |
| Zdroj: | BMJ. 2:711-713 |
| ISSN: | 1468-5833 0959-8138 |
| DOI: | 10.1136/bmj.2.5973.711 |
| Popis: | A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31% of 49 women receiving nafoxidine and in 14% of 49 receiving ethinyloestradiol. The differences in remission rates was almost significant (0.05 less than P less than 0.10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|